The first 2-drug complete regimen for HIV-infected adults who have never received ART
Dolutegravir and lamivudine have been approved by the US FDA as the first fixed-dose, complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of the drug.Currently, the standard of care for patients who have never been treated is a 3-drug regimen.W
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies